Vol 26, No 3 (2021)
Research paper
Published online: 2021-03-26
Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
Rep Pract Oncol Radiother 2021;26(3):325-340.
Abstract
BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality.
The aim of the study was to evaluate the safety and efficacy of adrenal gland SBRT in oligometastatic and oligoprogressive disease.
MATERIALS AND METHODS: In this retrospective study, we performed a single-institution analysis of 26 adrenal lesions from 23 patients with oligometastatic or oligoprogressive disease treated from 2013 to 2019 with the goal of achieving durable local control. Palliative cases were excluded. Radiation dosimetry data was collected. Kaplan Meier product estimator and Cox proportional hazards regression analysis were used for statistical analysis.
RESULTS: The median dose was 36 Gy in 3 fractions (range: 24–50 Gy and 3–6 fractions) with a median biologically effective dose (BED10) of 72 (range: 40–100). 1-year local control rate was 80% and median local control was not achieved due to a low number of failures. 1- and 2-year overall survival rates were 66% and 32%. Toxicity was mild with only one case of grade 2 nausea and no grade 3–5 toxicity. Higher neutrophil to lymphocyte ratio was associated with worse overall survival and a trend toward worse progression-free survival. In addition, worse performance status and lower BED10 were associated with worse survival. No such association could be shown for primary tumor location, histology, size or stage.
CONCLUSION: Adrenal SBRT for oligometastatic or oligoprogressive disease is a safe and effective form of treatment.
Keywords: adrenal metastasesstereotactic body radiotherapySBRToligometastatic diseaseoligoprogressive diseasemetastatic disease
References
- Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008; 26(7): 1142–1147.
- Mitchell IC, Nwariaku FE. Adrenal masses in the cancer patient: surveillance or excision. Oncologist. 2007; 12(2): 168–174.
- Welch BT, Callstrom MR, Carpenter PC, et al. A single-institution experience in image-guided thermal ablation of adrenal gland metastases. J Vasc Interv Radiol. 2014; 25(4): 593–598.
- Frenk NE, Daye D, Tuncali K, et al. Local Control and Survival after Image-Guided Percutaneous Ablation of Adrenal Metastases. J Vasc Interv Radiol. 2018; 29(2): 276–284.
- Short S, Chaturvedi A, Leslie MD. Palliation of symptomatic adrenal gland metastases by radiotherapy. Clin Oncol (R Coll Radiol). 1996; 8(6): 387–389.
- Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10.
- Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185): 2051–2058.
- Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016; 17(12): 1672–1682.
- Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018; 4(1): e173501.
- Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37(8): 4078–4101.
- Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19(1): 816.
- Oshiro Y, Takeda Y, Hirano S, et al. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol. 2011; 34(3): 249–253.
- Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009; 75(1): 71–75.
- Shah MM, Isrow D, Fareed MM, et al. Single institution experience treating adrenal metastases with stereotactic body radiation therapy. J Cancer Res Ther. 2019; 15(Supplement): S27–S32.
- Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys. 2012; 82(2): 919–923.
- Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011; 187(4): 245–251.
- Torok J, Wegner RE, Burton SA, et al. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2011; 7(1): 145–151.
- Guiou M, Mayr N, Kim E, et al. Stereotactic body radiotherapy for adrenal metastases from lung cancer. J Radiat Oncol. 2012; 1(2): 155–163.
- Burjakow K, Fietkau R, Putz F, et al. Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity. Strahlenther Onkol. 2019; 195(3): 236–245.
- Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 2012; 51(5): 618–623.
- Katoh N, Onimaru R, Sakuhara Y, et al. Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol. 2008; 87(3): 418–424.
- Rudra S, Malik R, Ranck MC, et al. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat. 2013; 12(3): 217–224.
- Desai A, Rai H, Haas J, et al. A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience. Front Oncol. 2015; 5: 185.
- Haidenberger A, Heidorn SC, Kremer N, et al. Robotic Radiosurgery for Adrenal Gland Metastases. Cureus. 2017; 9(3): e1120.
- Zhao X, Zhu X, Zhuang H, et al. Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China. Sci Rep. 2020; 10(1): 7836.
- Mills MN, Reddy AV, Richardson L, et al. The Prognostic Role of Pretreatment Neutrophil to Lymphocyte Ratio (NLR) in Malignant Adrenal Lesions Treated With Stereotactic Body Radiation Therapy (SBRT). Am J Clin Oncol. 2019; 42(12): 945–950.
- Toesca DAS, Koong AJ, von Eyben R, et al. Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. Adv Radiat Oncol. 2018; 3(4): 621–629.
- Ahmed KA, Barney BM, Macdonald OK, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013; 36(5): 509–513.
- Li J, Shi Z, Wang Z, et al. Treating adrenal tumors in 26 patients with CyberKnife: a mono-institutional experience. PLoS One. 2013; 8(11): e80654.
- Gamsiz H, Beyzadeoglu M, Sager O, et al. Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. Tumori. 2015; 101(1): 98–103.
- Chance WW, Nguyen QN, Mehran R, et al. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017; 7(3): e195–e203.
- Plichta K, Camden N, Furqan M, et al. SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Radiat Oncol. 2017; 2(4): 581–587.
- Buergy D, Rabe L, Siebenlist K, et al. Treatment of Adrenal Metastases with Conventional or Hypofractionated Image-guided Radiation Therapy - Patterns and Outcomes. Anticancer Res. 2018; 38(8): 4789–4796.
- Franzese C, Franceschini D, Cozzi L, et al. Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Res Treat. 2017; 49(1): 20–28.
- Scouarnec C, Pasquier D, Luu J, et al. Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases. Front Oncol. 2019; 9: 732.
- Yaprak GI, Gemici C, Demir H, et al. Stereotactic Body Radiotherapy for Adrenal Gland Metastases: Single-Center Experience. Turk J Oncol. 2019; 34(4): 291–7.
- Celik E, Semrau R, Baues C, et al. Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(9): 5285–5291.
- König L, Häfner MF, Katayama S, et al. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiat Oncol. 2020; 15(1): 30.
- Figura NB, Oliver DE, Mohammadi H, et al. Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution Experience. Am J Clin Oncol. 2020; 43(2): 107–114.
- Chen WC, Baal JD, Baal U, et al. Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients. Int J Radiat Oncol Biol Phys. 2020; 107(1): 48–61.
- YB C. Adrenal insufficiency in Bilateral Adrenal Metastasis implemented SBRT. J Radiol Oncol. 2018: 009–011.
- Jones B, Dale RG, Deehan C, et al. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol). 2001; 13(2): 71–81.
- Viswanathan A, Creutzberg C, Craighead P, et al. International Brachytherapy Practice Patterns: A Survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2012; 82(1): 250–255.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–247.
- Common Terminology Criteria for Adverse Events (CTCAE) Version. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020; 38(25): 2830–2838.
- Tedeschi M. National Library of Medicine (US). 2016 July 28 — Identifier NCT02848196. An Image-guided SBRT for Adrenal Gland Metastasis in Oligometastatic Patients; 2019 Dec 20. https://clinicaltrials.gov/ct2/show/NCT02848196 (2020 May 27).
- Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6): dju124.
- Sebastian N, Wu T, Bazan J, et al. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2019; 134: 151–157.
- Chmura S, Winter K, Al-Hallaq H, et al. NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2019; 37(15 Suppl): TPS1117–TPS1117.
- Conibear J, Chia B, Ngai Y, et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 2018; 8(4): e020690.
- Theelen WS, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 [Epub ahead of print].
- Palacios MA, Bohoudi O, Bruynzeel AME, et al. Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases. Int J Radiat Oncol Biol Phys. 2018; 102(2): 426–433.